Angiotensin-converting enzyme inhibitors

Circulation

Volumn 97, Issue 14, 1998, Pages 1411-1420

  Brown, Nancy J ^a   Vaughan, Douglas E ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Blood pressure; Bradykinin; Drugs; Renin

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; ISOSORBIDE; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRILAT;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG COST; DRUG MECHANISM; FETUS MALFORMATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT INDICATION;

EID: 0032515917     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.14.1411     Document Type: Review

References (172)

1. Skidgel RA, Erdos E. Biochemistry of angiotensin I-converting enzyme. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. New York, NY: Raven Press Ltd: 1993:10.1-10.10.
2. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology. Diagnosis, and Management. New York, NY: Raven Press Ltd; 1990:1287-1317.
3. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37-48.
4. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol. 1993;221(suppl):S1-S9.
5. Doolittle RF. Angiotensin is related to the antitrypsin-antithrombin ovalbumin family. Science. 1983;222:417-419.
6. Erdos EG. The angiotensin I converting enzyme. Fed Proc. 1977;36:1760-1765.
7. Folkow B, Johansson B, Mellander S. The comparative effects of angiotensin and noradrenaline on consecutive vascular sections. Acta Physiol Scand. 1961;53:99-104.
8. Zimmerman BG, Sybenz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2:581-587.
9. Biron P, Koiw E, Nowaczynski W. The effects of intravenous infusions of valine-5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone. J Clin Invest. 1961;60:338-347.
10. Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Clin Endocrinol. 1977;74:251-259.
11. Bell L, Madri J. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.
12. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
13. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
14. Dostal DE, Booz GW, Baker KM. Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem. 1996;157:15-21.
15. Huckle WR, Earp HS. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res. 1994;5:177-194.
16. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharm Rev. 1993;45:205-251.
17. Proud D, Kaplan AP, Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol. 1988;6:49-83.
18. Vanhouttc PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658-667.
19. Stein JH, Congbalay RC, Karsh DL, Osgood RW, Ferris TF. The effect of bradykinin on proximal tubular sodium reabsorption in the dog: evidence for functional nephron heterogeneity. J Clin Invest. 1972;51:1709-1721.
20. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
21. Cascieri MA, Bull HG, Mumford RA, Patchett AA, Thornberry NA, Liang T. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol. 1984;25:287-293.
22. Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis. 1987;10:13-23.
23. Mira ML, Suva MM, Manso CF. The scavenging of oxygen free radicals by angiotensin convening enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann N Y Acad Sci. 1994;723:439-441.
24. Fabris B, Jackson B, Cubela R, Mendelsohn FAO, Johnston CI. Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol. 1989;16:309-313.
25. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther. 1982;220:63-69.
26. Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FAO. Inhibition of tissue angiotensin convening enzyme: quantitation by autoradiography. Hypertension. 1988;11:230-238.
27. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, Jones KH, Ferber F, Abrams WB, Gavras H, Brunner HR. Three new long-acting converting enzyme inhibitors: relationship between plasma converting enzyme and response to angiotensin I. Clin Pharmacol Ther. 1981;29:665-670.
28. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, Mckinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979;90:19-23.
29. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, Mckinstry DN. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978;298:991-995.
30. Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med. 1965;120:399-403.
31. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, Tallant EA. Angiotensin-(1-7): a new hormone of the angiotensin system. Hypertension. 1991;18(suppl III):III-126-III-133.
32. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2:277-284.
33. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
34. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
35. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
36. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Anti-hypertensive therapy with MK-421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972.
37. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 1982;49:1561-1563.
38. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15:S46-S56.
39. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of ACE inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 1996;279:703-712.
40. Swartz S, Williams G, Hollenberg N, Levine L, Dluhy R, Moore T. Captopril-induced changes in prostaglandin production. J Clin Invest. 1980;65:1257-1264.
41. Tanaka S, Shimamoto K, Ando T, Nakahashi Y, Ura N, Hosoda S, Ishida H, Yamaji I, Yokoyama T, Masuda A, Iimura O. Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alacepril. Clin Exp Hypertens. 1987;A9:605-609.
42. Dzau VJ, Swartz SL. Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1987;60:1101-1105.
43. Johnston CI, Millar JA, McGrath BP, Matthews PG. Long-term effects of captopril (SQ-14225) on blood pressure and hormone levels in essential hypertension. Lancet. 1979;2:493-496.
44. Shoback DM, Williams GH, Swartz SL, Davies RO. Hollenberg NK. Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. Cardiovasc Pharmacol. 1983;5:1010-1018.
45. 2 in essential hypertension. Nephron. 1986;44:40-45.
46. 2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients. Prostaglandins Leukot Med. 1983;11:143-150.
47. Witzgall H, Scherer B, Weber PC. Involvement of prostaglandins in the actions of captopril. Clin Sci. 1982;63:265S-267S.
48. Gerber JG, Giuliano F, Byyny RL, LoVerde M, Nies AS. The hypotensive action of captopril and enalapril is not prostacyclin dependent. Clin Pharmacol Ther. 1993;54:523-532.
49. Homych A, Safar M, Simon A, Levenson J, Bariety J, Milliez P. Effects of captopril on prostaglandin and natriuresis in patients with essential hypertension. Am J Cardiol. 1982;49:1524-1526.
50. Ogihara T, Maruyama A, Hata T, Mikami H, Nakamaru M, Naka T, Ohde H, Kumahara Y. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacal Ther. 1981;36:328-335.
51. Omata K, Abe K, Tsunoda K, Yasujima M, Chiba S, Sata M, Kudo K, Yoshinaga K. Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension. Clin Exp Hypertens. 1987;A9:569-574.
52. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, König W, Knolle J, Schölkens BA. Hoe 140 a new potent and long acting bradykinin antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
53. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostpoulos H, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. Hoe 140 a new potent and long acting bradykinin antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
54. 2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol 1994;113:717-722.
55. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.
56. Gainer JV, Morrow JD, King DJ, Brown NJ. HOE 140 attenuates the hypotensive effect of captopril in humans. Hypertension. 1997;30:497. Abstract.
57. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulatian. 1997;95:1115-1118.
58. Lund-Johansen P, Omvik P. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens. 1984;2:S49-S50.
59. Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension. 1983;5(suppl I):I-184-I-189.
60. Dunn GF, Oigman W, Ventura HO, Messerli FH, Kobrin I, Frolich ED. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 1984;53:105-108.
61. Simon AC, Levenson JA, Bouthier J, Maarek B, Safar ME. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol. 1985;7:S45-S51.
62. Cody RJ, Tarazi RC, Bravo EL, Fouad FM. Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med. 1978;55:453-459.
63. Fouad FM, Tarazi RC, Bravo EL. Cardiac and haemodynamic effects of enalapril. J Hypertens. 1983;1(suppl 1):135-142.
64. Fagard R, Amery A, Reybrouck T, Lijnen P, Billiet L. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol. 1980; 46:295-300.
65. Tarazi RC, Bravo EL, Fouad FM, Omvik P, Cody RJ. Hemodynamic and volume changes associated with captopril. Hypertension. 1980;2:576-585.
66. Muiesan G, Alicandri CL, Agabiti-Rosei E, Fariello R, Beschi M, Boni E, Castellano M, Moniti E, Muiesan L, Romanelli G, Zanielli A. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol. 1982;49:1420-1424.
67. Mimran A, Brunner HR, Turini GA, Waeber B, Brunner D. Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci. 1979;57:421S-423S.
68. Hollenberg NK, Meggs LG, Williams GH, Kau J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. 1981;20:240-245.
69. Atlas SA, Case DB, Sealey JE, Laragh JH, Mckinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension. 1979;1:274-280.
70. Vidt DG, Bravo EL, Fouad FM. Captopril. N Engl J Med. 1982;306:214-219.
71. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986;31:198-248.
72. Pool JL, Gennari J, Goldstein R, Kochar MS, Lewin AJ, Maxwell MH, McChesney JA, Mehta J, Nash DT, Nelson EB, Rastogi S, Rofman B, Weinberger M. Controlled multicenter study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987;3:S36-S42.
73. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol. 1980;2:339-346.
74. Given BD, Taylor T, Hollenberg NK, Williams GH. Duration of action and short-term hormonal responses to enalapril (MK-421) in normal subjects. J Cardiovasc Pharmacol. 1984;6:436-441.
75. Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras HP. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J. 1982;103:384-390.
76. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini CA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980;2:236-242.
77. Ujhelyi MR, Ferguson RJ, Vlasses PH. Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy. 1989;9:351-362.
78. Veterans Administration Co-operative Study Group of Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982;14:97S-101S.
79. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
80. Freis ED, Materson BJ, Flamenbaum W. Comparison of propanolol or hydrochlorothiazide alone for treatment of hypertension. III: evaluation of the renin-angiotensin system. Am J Med. 1983;74:1029-1041.
81. Creditor M, Loschky U. PRA in hypertension. Am J Med. 1967;43:371-382.
82. Wisenbaugh PE, Garst JB, Hull C, Freedman RJ, Matthews DN, Haddy M. Renin, aldosterone, sodium and hypertension. Am J Med. 1972;52:175-186.
83. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;26:124-130.
84. Dusing R, Kayser G, Wagner S, Scherf H, Glanzer K, Predel HG, Kramer HJ. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme. Am J Cardiol. 1987;59:50D-54D.
85. Guidicelli JF, Berdeaux A, Edouard A, Richer C, Jacolol D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. Br J Clin Pharmacol. 1985;20:211-218.
86. Ajayi AA, Campbell BC, Meredith PA, Kelman AW, Reid JL. The effect of captopril on the reflex control heart rate: possible mechanisms. Br J Clin Pharmacol. 1985;20:17-25.
87. Giannattasio C, Grassi G, Seravalle G, Morganti A, Zanchetti A, Mancia G. Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. Am Heart J. 1989;117:740-745.
88. Sixth report of the Joint National Committee on Detection. Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
89. Hansson L. The Captopril Prevention Project (CAPPP): description and status. Am J Hypertens. 1994;7:82S-83S.
90. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990;110:1361-1367.
91. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens. 1995;13(suppl):S11-S17.
92. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1994;53:1044-1049.
93. Gaudio C, Tanzilli G, Collatina S, Pagnotta P, Paknejad K, Campa PP. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance imaging. Cardiologia. 1992;37:789-791.
94. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
95. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
96. Cohn JN, Johnson G, Ziesche J, Frederick C, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
97. AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
98. Kober L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Allot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
99. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
100. Curtiss SC, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978;58:763-769.
101. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 1978;58:770-776.
102. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979;1:1213-1215.
103. Davis R, Ribner HS, Keung E, Sonnenblick EH, LeJemtel TH. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin converting enzyme. N Engl J Med. 1979;301:117-121.
104. Tarazi RC, Fouad FM, Ceimo JK, Bravo EL. Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. Am J Cardiol. 1979;44:1013-1019.
105. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980;302:1373-1379.
106. Levine TB, Franciosa JA, Cohn JN. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980;62:35-41.
107. Sharpe DN, Cuxon RJ, Douglas JE, Long B. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet. 1980;2:1154-1157.
108. Maslowski AH, Nicholls MG, Ikram H, Espiner EA. Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet. 1981;1:71-74.
109. Cody RJ, Covit A, Schaer G, Williams G. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. Am Heart J. 1982;104:1180-1183.
110. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
111. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
112. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
113. Vaughan DE, Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res. 1994;28:159-165.
114. Dahlof B. Effect of angiotensin II a blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens. 1995;9(suppl):S37-S44.
115. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
116. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57:84-95.
117. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
118. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
119. ISIS Collaborative Group. ISIS-4: randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation. 1993;88(suppl I):I-394.
120. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
121. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.
122. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med. 1995;46:455-456.
123. Borghi C, Ambrosioni E. Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1996;10:519-525.
124. Hayek T, Keidar S, Mei-Yi, Oiknine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apo E deficient mice. Circulation. 1995;92(suppl I):I-625.
125. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
126. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl):S65-S72.
127. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
128. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
129. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
130. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE, Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993;87:1969-1973.
131. Emeis JJ. Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions. 1992;38:285-291.
132. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemot. 1997;77:522-525.
133. Lees RS, Pitt B, Chan RC, Holmvang G, Dinsmore RE, Campbell LW, Haber HE, Kubaner MI, Cashin-Hemphill L. Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) trial. Am J Cardiol. 1996;78:1011-1016.
134. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Am J Cardiol. 1996;12:127-137.
135. Ichikawa I, Brenner BM. Glomerular actions of angiotensin II. Am J Med. 1984;76:43-49.
136. Anderson SG, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rat. J Clin Invest. 1986;77:1993-2000.
137. Fogo A, Yoshida Y, Yared A, Ichikawa I. Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys. Kidney Int. 1990;38:1068-1074.
138. Ruin-Ortega M, Gomez-Garre D, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens. 1994;12:S51-S58.
139. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of imerventional studies to preserve renal function. J Clin Pharmacal. 1995;35:73-80.
140. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
141. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticeili C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
142. Cowie CC, Harris MI, Silverman RE, Johnson EW, Rust KF. Effect of multiple risk factors on differences between blacks and whites in the prevalence of non-insulin-dependent diabetes mellitus in the United States. Am J Epidemiol. 1993;137:719-732.
143. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
144. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R. Kawaguchi Y, Kubo H, Ichikawa I, Sakai O. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest. 1995;96:2162-2169.
145. Parving HH, Jacobsen P, Tamow L, Rossing P, Lecerf L, Poirier O, Cambien F. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ. 1996;313:591-594.
146. Hodsman GP, Isles CG, Murray CD, Usherwood TP, Webb I, Robertson JI. Factors related to first dose hypotensive effect of captopril: prediction and treatment. BMJ. 1983;286:832-834.
147. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. JAMA. 1980;244:2551-2552.
148. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med. 1982;73:719-725.
149. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. Arch Int Med. 1984;144:2371-2372.
150. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373-376.
151. Dzau VJ. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am J Kidney Dis. 1987;10:74-80.
152. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J Clin Res. 1984;288:844-845.
153. Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Physiol. 1984;246:F897-F906.
154. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993;44:545-550.
155. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992; 117:234-242.
156. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141-144.
157. Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol. 1995;48:851-857.
158. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet. 1992;339:372. Letter.
159. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, Ewan PW. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260:967-970.
160. Brown NJ, Ray WA, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
161. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol. 1995;9:382-385.
162. Pryde PG, Sedman SB, Nugent CE, Barr MJ. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrology. 1993;3:1575-1582.
163. DiBianco R. Adverse reactions with angiotensin converting enzyme inhibitors. Med Toxicol. 1986;1:122-141.
164. Cooper RA. Captopril-associated neutropenia: who is at risk? Arch Intern Med. 1983;143:659-660.
165. Erslev AJ, Alexander JC, Caro J, Boyd RL. Hematologic side effects of captopril and associated risk factors. Cardiovasc Rev Rep. 1982;3:660-671.
166. Edwards IR, Coulter DM, Beasley DM, MacIntosh D. Captopril: 4 years of post marketing surveillance of all patients in New Zealand. Br J Clin Pharmacol. 1987;23:529-536.
167. Goodfield MJ, Millard LG. Severe cutaneous reactions to captopril. BMJ. 1985;290:1111.
168. Dixon CM, Fuller RW, Bames PJ. The effect of an angiotensin converting enzyme inhibitor, ramipril. on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. Br J clin Pharmacol. 1987;23:91-93.
169. Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. Am J Med. 1984;77:23-35.
170. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens. 1987;5:121-128.
171. Moore TJ, Crantz FR, Hollenberg NK, Koletsky RJ, Leboff MS, Swartz SL, Levine L, Podolsky S, Dluhy RG, Williams GH. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension. 1981;3:168-173.
172. Abe K, Itoh T, Imai Y, Sato M, Haruyuma T, Sakurai Y, Goto T, Otsuka Y, Yoshinaga K. Implication of endogenous prostaglandin synthesis in the anti-hypertensive effect of captopril, SQ 14225, in low renin hypertension. Jpn Circ J. 1980;44:422-425.